Newer monoclonal antibodies such as Rituxan have proved very useful in chronic or refractory ITP and studies are ongoing to determine the best regimens using this form of immune modulation.

• 新型的单克隆抗体，如利妥昔单抗，已被证明对慢性或顽固性ITP非常有效，而且有关这一免疫治疗最佳方案的研究正在进行中。